Biomedix Incubator Ltd. (TASE:BMDX) said today that biotech company Israel Biomedical Innovations (IBI), the company previously called Endogun, has signed additional distribution agreements for its first gynecological product throughout Europe. The product is already distributed in Germany.
The new deals cover France, Greece, Cyprus, Portugal, Spain, and Holland.
Biomedix's share price rose 2.8% by mid-afternoon. The shares have gained 56% so far in 2010.
Biomedix unit Meytav Technological Enterprises Innovation Center Ltd. owns 9.4% of IBI, and another Biomedix subsidiary, Spearhead, owns 10.8%.
Biomedix owns 85% of Meytav and 56.68% of Spearhead.
IBI has developed soft tissue attachment products for minimally invasive surgery. Its primary product, the EndoFast Reliant system, is used in the treatment of pelvic organ prolapse. The company has US FDA clearance as well as CE Marking for marketing its products.
Biomedix's share price rose 2.8% by mid-afternoon. The shares have gained 56% so far in 2010.
Published by Globes [online], Israel business news - www.globes-online.com - on March 4, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010